NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis → Memorial Day Sale! Get 90% OFF Behind the Markets! (From Behind the Markets) (Ad) Free LNTH Stock Alerts $78.22 -0.78 (-0.99%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$78.10▼$80.7250-Day Range$56.52▼$82.8752-Week Range$50.20▼$99.01Volume857,188 shsAverage Volume1.08 million shsMarket Capitalization$5.42 billionP/E Ratio11.94Dividend YieldN/APrice Target$99.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Lantheus alerts: Email Address Lantheus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside26.8% Upside$99.17 Price TargetShort InterestBearish7.14% of Shares Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment1.41Based on 9 Articles This WeekInsider TradingAcquiring Shares$57.41 M Bought Last QuarterProj. Earnings Growth-9.40%From $6.17 to $5.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.43 out of 5 starsMedical Sector106th out of 923 stocksDiagnostic Substances Industry2nd out of 13 stocks 3.4 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLantheus has only been the subject of 3 research reports in the past 90 days.Read more about Lantheus' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.14% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Lantheus has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 4.1 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Lantheus this week, compared to 6 articles on an average week.Search Interest22 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows8 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have bought 829.36% more of their company's stock than they have sold. Specifically, they have bought $57,409,487.00 in company stock and sold $6,177,295.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to decrease by -9.40% in the coming year, from $6.17 to $5.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 11.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 11.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.47.Price to Book Value per Share RatioLantheus has a P/B Ratio of 5.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Lantheus Stock (NASDAQ:LNTH)Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More LNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Stock News HeadlinesMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksMay 20, 2024 | insidertrades.comInsider Trading is Good News for These Stocks (LNTH)May 16, 2024 | insidertrades.comInsider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Sells 341 Shares of StockMay 23 at 12:36 PM | seekingalpha.comLeading The Growth Of Radiopharmaceuticals: Mini Deep Dive On LantheusMay 16, 2024 | bizjournals.comAfter CEO change, Lantheus announces more new C-suite additionsMay 16, 2024 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Short Interest Up 6.5% in AprilMay 15, 2024 | msn.comLantheus Stock (NASDAQ:LNTH): High Growth Powered by Radiopharma InnovationsMay 15, 2024 | globenewswire.comLantheus Announces Executive Appointments to Accelerate InnovationMay 5, 2024 | finance.yahoo.comLantheus Holdings, Inc. Just Beat EPS By 60%: Here's What Analysts Think Will Happen NextMay 5, 2024 | seekingalpha.comLantheus Holdings: Powerful First QuarterMay 3, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Lantheus (LNTH)May 3, 2024 | markets.businessinsider.comEvaluating Lantheus Holdings: Insights From 5 Financial AnalystsMay 3, 2024 | finance.yahoo.comLantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2024 Earnings Call TranscriptMay 3, 2024 | msn.comLNTH Stock Earnings: Lantheus Holdings Beats EPS, Beats Revenue for Q1 2024May 3, 2024 | finance.yahoo.comLantheus Holdings Inc (LNTH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 2, 2024 | sfgate.comLantheus Holdings: Q1 Earnings SnapshotMay 2, 2024 | finance.yahoo.comLantheus Holdings Inc (LNTH) Surpasses Q1 2024 Revenue and Earnings EstimatesMay 2, 2024 | globenewswire.comLantheus Reports First Quarter 2024 Financial ResultsApril 30, 2024 | finance.yahoo.comLantheus Holdings (NASDAQ:LNTH) Knows How To Allocate Capital EffectivelyApril 29, 2024 | msn.comBaxter (BAX) to Report Q1 Earnings: What's in the Cards?April 18, 2024 | globenewswire.comLantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern TimeApril 15, 2024 | finance.yahoo.comLantheus Holdings (LNTH) Stock Moves -0.89%: What You Should KnowApril 12, 2024 | fool.com2 Magnificent Stocks You Probably Never Heard OfApril 10, 2024 | investorplace.comWall Street Favorites: 3 Russell 2000 Stocks With Strong Buy Ratings for April 2024March 24, 2024 | finance.yahoo.comInvesting in Lantheus Holdings (NASDAQ:LNTH) three years ago would have delivered you a 198% gainSee More Headlines Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees834Year FoundedN/APrice Target and Rating Average Stock Price Target$99.17 High Stock Price Target$100.00 Low Stock Price Target$96.00 Potential Upside/Downside+26.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$6.55 Trailing P/E Ratio11.94 Forward P/E Ratio12.68 P/E GrowthN/ANet Income$326.66 million Net Margins33.72% Pretax Margin43.45% Return on Equity54.10% Return on Assets25.70% Debt Debt-to-Equity Ratio0.59 Current Ratio4.84 Quick Ratio4.55 Sales & Book Value Annual Sales$1.30 billion Price / Sales4.18 Cash Flow$6.68 per share Price / Cash Flow11.71 Book Value$13.64 per share Price / Book5.73Miscellaneous Outstanding Shares69,310,000Free Float68,273,000Market Cap$5.42 billion OptionableOptionable Beta0.52 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 65)CEO & Director Comp: $139.19kMr. Paul M. Blanchfield (Age 42)President Comp: $1.18MMr. Robert J. Marshall Jr. (Age 57)CFA, CFO & Treasurer Comp: $1.3MMr. Daniel M. Niedzwiecki (Age 46)Chief Administrative Officer, General Counsel & Corporate Secretary Comp: $920.09kDr. Jean-Claude Provost M.D.Chief Medical OfficerMs. Andrea Sabens (Age 45)Chief Accounting Officer Ms. Dorothy BarrSenior Vice President of Manufacturing & Technical OperationsMr. Mark Richard KinarneySenior Director of Investor RelationsMs. Linda S. Lennox (Age 58)VP of Corporate Communications & Chief of Staff Ms. Carol Walker (Age 61)Senior Vice President of Quality More ExecutivesKey CompetitorsRiot PlatformsNASDAQ:RIOTNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 1,269,900 shares on 5/24/2024Ownership: 2.140%Cetera Advisors LLCBought 9,085 shares on 5/24/2024Ownership: 0.013%Burney Co.Bought 41,641 shares on 5/22/2024Ownership: 0.060%Swedbank ABBought 423,300 shares on 5/21/2024Ownership: 0.611%LRI Investments LLCBought 3,391 shares on 5/21/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions LNTH Stock Analysis - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price target for 2024? 7 analysts have issued 12 month target prices for Lantheus' stock. Their LNTH share price targets range from $96.00 to $100.00. On average, they expect the company's share price to reach $99.17 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2024? Lantheus' stock was trading at $62.00 at the beginning of the year. Since then, LNTH shares have increased by 26.2% and is now trading at $78.22. View the best growth stocks for 2024 here. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its quarterly earnings data on Thursday, May, 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.11. The medical equipment provider had revenue of $369.98 million for the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a net margin of 33.72% and a trailing twelve-month return on equity of 54.10%. What ETFs hold Lantheus' stock? ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), SPDR S&P Health Care Equipment ETF (XHE), Tema Oncology ETF (CANC), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Harbor Small Cap Explorer ETF (QWST), Burney U.S. Factor Rotation ETF (BRNY), Principal U.S. Small-Cap Multi-Factor ETF (PSC) and Pacer US Cash Cows Growth ETF (BUL). What guidance has Lantheus issued on next quarter's earnings? Lantheus updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of 1.810-1.860 for the period, compared to the consensus EPS estimate of 1.660. The company issued revenue guidance of $380.0 million-$390.0 million, compared to the consensus revenue estimate of $356.1 million. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.62%), Janus Henderson Group PLC (5.54%), Westfield Capital Management Co. LP (2.82%), Farallon Capital Management LLC (2.14%), Reinhart Partners LLC. (2.14%) and Price T Rowe Associates Inc. MD (2.00%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Lantheus Alpha Therapy, Llc, Mary Anne Heino, Minnie Baylor-Henry, Paul Blanchfield and Robert J Jr Marshall. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LNTH) was last updated on 5/26/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s PRIME is Set to Shock the WorldInvestorPlaceShocking $16T Elon Musk Crypto LeakCrypto 101 MediaJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsNew Options need New Trading StrategiesNetpicks$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe Presidential candidate you should REALLY be worried aboutStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
